Detailed Explanation
Orphan Drug Designation was established by the Orphan Drug Act of 1983 to address a market failure in pharmaceutical development: rare diseases, while individually uncommon, collectively affect millions of patients, yet the limited market size for any single rare disease often made development economically unfeasible. The orphan drug program provides incentives that offset the commercial challenges of rare disease drug development, resulting in hundreds of new treatments for conditions that might otherwise have remained without approved therapies.
The incentives associated with Orphan Drug Designation are substantial and have proven effective in stimulating rare disease drug development. Designated products receive seven years of marketing exclusivity upon approval, during which the FDA will not approve the same drug for the same indication from another company, even if patent protection has expired. Additional incentives include tax credits for clinical trial costs, waiver of application fees, and eligibility for grants supporting clinical research. These benefits can significantly improve the economic viability of rare disease drug development.